Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors slow renal disease progression and reduce cardiac morbidity and mortality in patients with diabetes. Patients' out-of-pocket costs pose a barrier to using this effective therapy. OBJECTIVE: To estimate the cost-effectiveness to Medicare of first-dollar coverage (no cost sharing) of ACE inhibitors for beneficiaries with diabetes. DESIGN: Markov model with costs and benefits discounted at 3%. DATA SOURCES: Published literature and Medicare claims data. TARGET POPULATION: 65-year-old Medicare beneficiary with diabetes. TIME HORIZON: Lifetime. PERSPECTIVE: Medicare and societal. INTERVENTIONS: We evaluated Medicare first-dollar coverage of ACE inhibitors compared with current practice (no coverage) and the new Medicare drug benefit. OUTCOME MEASURES: Costs (2003 U.S. dollars), quality-adjusted life-years (QALYs), life-years, and incremental cost-effectiveness. RESULTS OF BASE-CASE ANALYSIS: Compared with current practice, first-dollar coverage of ACE inhibitors saved both lives and money (0.23 QALYs gained and 1606 USD saved per Medicare beneficiary). Compared with the new Medicare drug benefit, first-dollar coverage remained a dominant strategy (0.15 QALYs gained, 922 USD saved). RESULTS OF SENSITIVITY ANALYSIS: Results were most sensitive to our estimate of increase in ACE inhibitor use; however, if ACE inhibitor use increased by only 7.2% (from 40% to 47.2%), first-dollar coverage would remain life-saving at no net cost to Medicare. In analyses conducted from the societal perspective, benefits were similar and cost savings were larger. LIMITATIONS: Results depend on accuracy of the underlying data and assumptions. The effect of more generous drug coverage on medication adherence is uncertain. CONCLUSIONS: Medicare first-dollar coverage of ACE inhibitors for beneficiaries with diabetes appears to extend life and reduce Medicare program costs. A reduction in program costs may result in more money to spend on other health care needs of the elderly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · cited 1×
“The HOPE trial demonstrated that ACE inhibitors improve both renal and cardiovascular outcomes, compared with placebo, in patients with diabetes (13, 14, 35).”
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
The Continuing Epidemics of Obesity and Diabetes in the United States
Mokdad, A. H. (2001) · JAMA · doi:10.1001/jama.286.10.1195 · Cited by 2,730
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440 · cited 1×
“The HOPE trial demonstrated that ACE inhibitors improve both renal and cardiovascular outcomes, compared with placebo, in patients with diabetes (13, 14, 35).”
Grundy, S. M., Pasternak, R., Greenland, P., Smith, S., & Fuster, V. (1999) · Circulation · doi:10.1161/01.cir.100.13.1481 · Cited by 1,315
Diabetes trends in the U.S.: 1990-1998.
Mokdad, A. H., Ford, E. S., Bowman, B. A., Nelson, D. E., Engelgau, M. M., Vinicor, F., & Marks, J. S. (2000) · Diabetes Care · doi:10.2337/diacare.23.9.1278 · Cited by 1,042
Cited by
Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review
Li, R., Zhang, P., Barker, L. E., Chowdhury, F. M., & Zhang, X. (2010) · Diabetes Care · doi:10.2337/dc10-0843 · Cited by 491
Interventions Aimed at Reducing Use of Low-Value Health Services: A Systematic Review
Colla, C. H., Mainor, A. J., Hargreaves, C., Sequist, T., & Morden, N. (2017) · Medical Care Research and Review · doi:10.1177/1077558716656970 · Cited by 357
Chernew, M. E., Rosen, A. B., & Fendrick, A. M. (2007) · Health Affairs · doi:10.1377/hlthaff.26.2.w195 · Cited by 344
Self-citationBehavioral Hazard in Health Insurance *
Baicker, K., Mullainathan, S., & Schwartzstein, J. (2015) · The Quarterly Journal of Economics · doi:10.1093/qje/qjv029 · Cited by 247
Vijan, S., Sussman, J. B., Yudkin, J. S., & Hayward, R. A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2894 · Cited by 185
Self-citation
Metadata
- Authors
- Rosen, A. B., Hamel, M. B., Weinstein, M. C., Cutler, D. M., Fendrick, A. M., & Vijan, S.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2005-07-19
- Volume
- 143
- Issue
- 2
- Pages
- 89-99
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2020462643
- Cited by
- 131
- References
- 17
- FWCI
- 41.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes. https://app.cochat.ai/papers/10.7326/0003-4819-143-2-200507190-00007
- The paper
- Rosen, A. B., Hamel, M. B., Weinstein, M. C., Cutler, D. M., Fendrick, A. M., & Vijan, S. (2005). Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-143-2-200507190-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.